Thursday, August 13, 2020

WuXi AppTec Reports Strong 2019 Annual Results

WuXi AppTec Reports Strong 2019 Annual Results Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year to RMB2,407 Million Adjusted Diluted...

WuXi AppTec Wuhan Site Resumes Operation

SHANGHAI, March 12, 2020 – WuXi AppTec announced that the company’s Wuhan site resumed operations yesterday, in compliance with local regulations and global COVID-19 health and safety guidelines. Operations at the Wuhan facility, which provides discovery chemistry services, will ramp up over the coming days...

WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday

WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday SHANGHAI, February 12, 2020 - With the end of the extended Lunar New Year holiday, WuXi AppTec sites in China have resumed operations today, with the exception of our site...

WuXi Healthcare Forum 2020 – Solving Tomorrow’s Health Challenges

WuXi Healthcare Forum 2020 – Solving Tomorrow’s Health Challenges To Be Determined|The St. Regis Shanghai Jingan, Shanghai, China Dear Colleagues and Friends, Given current efforts to address the coronavirus outbreak, the organizing committee of the WuXi Healthcare Forum has decided to postpone this event, originally scheduled for...

WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

New AAV Vector Suspension platform complements integrated capabilities – enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally. January 13, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS